• E-ISSN 2636-7688
  • Call Us: +90 422 341 06 60 / 1224
  • Email Us: dergi@inonu.edu.tr

Formerly Journal of Turgut Ozal Medical Center - ISSN 1300-1744

Current Issues

Serum soluble TWEAK levels in non-alcoholic fatty liver disease (p. 1594-9)

Serum soluble TWEAK levels in non-alcoholic fatty liver disease (p. 1594-9)

Ramazan Dertli1, Murat Biyik2, Ramazan Yolaçan3, Muharrem Keskin2, Yusuf Kayar1, Saliha Uysal4, Huseyin Ataseven2, Hakki Polat3, Nurcan Unver5, Ali Demir2, Mehmet Asil2
1Van Education and Research Hospital, Department of Internal Medicine, Division of Gastroenterology, Van, Turkey
2Necmettin Erbakan University, Meram Faculty of Medicine, Department of Internal Medicine, Division of Gastroenterology, Meram, Konya, Turkey
3Necmettin Erbakan University, Meram Faculty of Medicine, Department of Internal Medicine Meram, Konya, Turkey
4Necmettin Erbakan University, Meram Facultyof Medicine, Department of Biochemistry. Meram, Konya, Turkey
5Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Department of pathology, Istanbul

Abstract

Aim: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. The exact pathogenesis of NAFLD has not been fully elucidated. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a member of TNF superfamily and it has been implicated in the pathogenesis of several diseases including liver inflammation and fibrosis. Current study was conducted to evaluate serum sTWEAK levels in patients with NAFLD.
Material and Methods: Seventeen patients with biopsy proven non-alcoholic steatohepatitis (NASH), 22 patients with simple hepatosteatosis and 30 healthy controls were included in the study and serum sTWEAK concentrations were measured using commercial ELISA kits.
Results: Mean serum sTWEAK concentration was significantly lower in the NASH group when compared to the simple hepatosteatosis group and healthy controls (199.6±101.2 pg/mL, 246.1±65.7 pg/mL and 277.6±117.6 pg/mL respectively, p=0.029). ROC analyses for sTWEAK to differentiate NASH patients from healthy controls and from simple hepatosteatosis revealed that AUC for sTWEAK was 0.712 (%95 CI, 0.543-0.880). For the specified cut off value, 171.1 pg/mL positive and negative predictive values calculated were 64.3% and 85.5% respectively.
Conclusion: Serum sTWEAK concentration is decreasedin patients with NASH when compared to patients with simple hepatosteatosis and healthy controls.
Keywords: Nonalcoholic steatohepatitis; tumor necrosis factor-like weak inducer of apoptosis; sTWEAK; fibroblast growth factor-inducible 14; Fn 14. 

 

DOWNLOAD
doi: 10.5455/annalsmedres.2019.05.248

DownloadXML


demo

Annals of Medical Research is the scientific official journal of the Inonu University Faculty of Medicine. It is published monthly. The essential aim of the Annals of Medical Research is to publish scientifically high quality clinical and experimental research articles on fields of medicine which can contribute to the literature data. In addition, review articles, case reports, editorials, letters to the editors and manuscripts on publication ethics and medical history, which can contribute to the education and practices of physicians and health sector professionals within the scope of the journal’s target audience and which can increase the level of scientific communication between the authors and readers, are included in the scope of the journal.

 

Recent News

All News

Links

Certificate of General Impact Factor

Email Newsletter

Sign up for the latest Inonu University Our new article, updates....